How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs

The pharmaceutical industry is facing a sizable patent cliff, with hundreds of billions in sales at risk as more than 190 products lose exclusivity between 2022 and 2030. The industry has faced large-scale patent cliffs before, including in 2016, when many major sellers, such as Crestor (rosuvastatin) and Glivec (imatinib), went off-patent. However, while the 2016 patent cliff was projected to erode $100 billion in brand-name sales, the current expirations will put over $300 billion sales at risk between 2023 and 2028, Eduardo Schur, EY US health sciences & wellness commercial strategy and R&D lead, told BioSpace.